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1. Introduction 
Portal vein thrombosis (PVT) refers to the complete or partial obstruction of blood flow in 
the portal vein, due to the presence of a thrombus into the vessel lumen  (Bayraktar & 
Harmanci, 2006) 
Cavernous transformation of portal vein consists in the development of a network of 
tortuous collateral vessels bypassing the obstructive area due to chronic PVT. First described 
in 1869 by Balfour and Stewart, it was Köbrich in 1928 that used for the first time the term of 
“cavernoma” to define the newly developed network of small vessels as a result of 
recanalization of the thrombotic portal vein. Once the liver blood supply decreases 
significantly, the compensatory mechanism is activated and collaterals begin to form within 
a few days after the obstruction and organize into a cavernous transformation in 3-5 weeks. 
(Cai, 2009)  
Based on a case previously communicated by us - (A case of portal cavernoma – associated 
thrombocythemia - A. Rosu, C. Searpe, V. Sbarcea, Z. Stoica, M. Popescu. J Gastrointestin 
Liver Dis 2007 16(1): 97-100), a review of the published English literature was performed 
using PubMed® (http://www.ncbi.nlm.nih.gov/PubMed) and Medline database. The 
search of screened articles was made for the keywords “portal vein thrombosis”, “portal 
cavernoma” and "myeloproliferative disorders" (MPD). Articles were selected if a review of 
the title and/or abstract suggested the association of portal vein thrombosis with cavernous 
transformation in patients with myeloproliferative diseases.  
2. Epidemiology 
2.1 Epidemiology of PVT 
In the era of continuous and impressive development of the imagistic techniques  (contrast-
enhanced ultrasound, spiral CT-scan, high definition MRI etc) the diagnosis of portal vein 
thrombosis (PVT) is no longer a rare condition since recent studies estimates it’s incidence at 
1,1% in the general population (Ogren et al., 2006). Also PVT is considered to account for 5 
to 10% of patients with portal hypertension (Wang et al., 2005). 
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The concept of PVT as a rare disease is mainly based on clinical series and case reports 
(Amitrano, 2004), therefore accurate epidemiological data about PVT are difficult to obtain. 
An epidemiological study performed and conducted in southern Sweden (Ogren et al., 2006) 
based on the study of 23 796 autopsies, reported the incidental finding of a PVT in about 1% 
of the general population. Authors reported that 28% of PVT patients had cirrhosis, 23% 
primary and 44% secondary hepatobiliary malignancy, 10% major abdominal infectious or 
inflammatory disease and 3% had a myeloproliferative disorder. Other studies reveal that 
prevalence of PVT in autopsy studies in USA and Japan ranges from 0.05% to 0.5% (Wang et 
al., 2005).  
Actually, thanks to the availability of more sensitive and less invasive imaging, together 
with the existence of curative or palliative procedures, PVT is routinely investigated and 
defined without any difficulty. Thus, PVT seems more frequent than expected: it is 
estimated to be responsible for 5%-10% of the overall cases of portal hypertension, which 
can be 40% in western countries (Wang et al., 2005). 
2.2 Epidemiology of MPD with PVT  
The annual incidence of myeloproliferative syndrome is 2,1-3,5 per 100000 peoples (Kutti & 
Ridell, 2001). From the four entities comprising the myeloproliferative syndrome according 
to the FAB classification (essential thrombocythemia, polycythaemia vera, chronic 
myelogenous leukemia and idiopathic myelofibrosis), essential thrombocythemia is 
considered the most frequent disease with an annual incidence of 0,7-2,5 per 100000 peoples 
(Cai et al., 2009; Girodon et al., 2009; Rollison et al., 2008). The transformation to acute 
myelogenous leukemia is recorded in 0,6-5% of patients and the overall 10-year survival rate 
is 64-80% (Fenaux et al., 1990). 
In many patients with non-cirrhotic non-malignant PVT, a systemic, thrombophilic risk 
factor is often present. Over the last two decades, some of, either inherited or acquired, 
systemic conditions that result in a thrombogenic phenotype have been identified as risk 
factors for the development of PVT. 
MPD remains the major latent or patent cause of extrahepatic PVT (Diaz et al., 2001 ; Valla et 
al., 1988; Valla & Condat, 2000). In non-cirrhotic and non-tumoral PVT cases in the West, 
MPD (i.e. polycythaemia vera, essential thrombocythaemia and myelofibrosis) with a 
combination of several prothrombotic factors constitute the most common identifiable cause 
with an estimated prevalence of 30%-60% (Cai et al., 2009; Kiladjian et al., 2006; Kutti & 
Ridell, 2001). In another study, a myeloproliferative disorder (MPD) was found in 37% of 
patients with non-cirrhotic non-malignant PVT (Kiladjian et al., 2006). 
Essential thrombocytaemia (ET) is frequently associated with thrombotic complications in the 
large abdominal vessels. It was reported a prevalence of 4% for abdominal vein thrombosis in 
460 consecutive patients with ET (Gangat et al., 2006), but did not provide detailed information 
on portal vein thrombosis. The risk factors for thrombosis in ET patients include age, 
thrombotic history, cardiovascular risk factors and genetic or acquired thrombophilia 
(Landolfi et al., 2008). It seems likely that elevated platelet count is involved in thrombotic 
events in ET. However, the degree of elevation does not appear to be important, relatively low 
platelet counts often being associated with thrombosis (Harrison, 2005). 
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3. Etiology and pathogenesis 
Portal vein thrombosis is the result of a complex mechanism involving multiple local and 
systemic risk factors with effect on coagulability, blood flow and endothelium integrity. 
Blood flow obstruction in the portal vein is the result of invasion, thrombosis, constriction 
and frequently, a combination of the above-mentioned mechanisms. A list of most common 
conditions associated with portal vein thrombosis is presented in table 1 and 2 (Chawla et 
al., 2009; Gurakan et al., 2004; Hoekstra & Janssen, 2009; Janssen, 2001; Rosendaal, 1999; 
Valla & Condat, 2000; Valla et al., 2002). 
 
Inherited 
Anticoagulant deficiency syndroms (antithrombin-III, protein-C, 
protein-S) 
Mutation involving coagulating factor II (G20210A) or V (G1691) 
Plasminogen deficiency 
MTHFR homozygote mutation TT677 
TAFI (thrombin activatable fibrinolysis inhibitor) gene mutation 
Sickle cell disease 
Acquired 
Myeloproliferative disorders (polycythemia vera, essential 
thrombocythemia) 
Paroxysmal nocturnal hemoglobinuria 
Antiphospholipidic syndrome 
Hyperhomocisteinemia 
Nephrotic syndrome 
Estro-progestative medication 
Pregnancy 
Autoimmune diseases 
Autoimmune hepatitis 
Primary biliary cirrhosis 
Systemic lupus erythematosus 
Rheumatoid arthritis 
Wegener disease 
Mixed connective tissue 
disease 
Behcet syndrome 
 
Table 1. Systemic hypercoagulability conditions associated with portal vein thrombosis 
Noteworthy are the local factors predisposing to portal location instead of peripheral 
venous thrombosis in patients with hypercoagulability associated diseases. These factors 
are: local inflammatory diseases, injury of the portal venous tract, liver cirrhosis and 
abdominal cancer (table 2). 
Although in most cases thrombosis of the portal vein has an identifiable cause, less than 20% 
are considered to be idiopathic. In children, umbilical vein sepsis and neonatal umbilical 
vein catheterization are the main causes of portal vein thrombosis. In adults, liver cirrhosis, 
abdominal malignant tumors and association of different hypercoagulability states explains 
the vast majority of portal vein thrombosis.  
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Liver cirrhosis  
Nodular regenerative hyperplasia  
Abdominal malignant neoplasia  Hepatocarcinoma  
Cholangiocarcinoma 
Liver metastasis 
Gallbladder cancer 
Pancreatic cancer 
Liver angiosarcoma 
Iatrogenic injury of the portal 
venous tract 
Endoscopic sclerotherapy of esophageal varices 
Alcoolisation/chemoembolisation/radiofrequency 
ablation of hepatic tumors 
TIPS / surgical porto-systemic shunt 
Hepatectomy or liver transplantation 
Splenectomy 
Umbilical vein catheterization 
Colectomy 
Gastrectomy  
Hepatobiliary surgery 
Gastric banding 
Fundoplication 
Portography 
Peritoneal dialysis 
Islet-cell injection 
Surgery of the portal tract 
Endothelial injury due to cytostatics (cisplatin, 
cyclophosphamide, methotrexate, 5-fluorouracil) or 
radiation therapy 
Local inflammatory diseases Omphalitis 
Cholecystitis 
Cholangitis 
Appendicitis 
Diverticulitis 
Acute or chronic pancreatitis 
Tuberculous lymphadenitis 
Inflammatory bowel diseases (Crohn’s disease, 
ulcerative colitis) 
Hepatic hydatid cyst 
Pylephlebitis (frequently due to Bacteroides 
bacteriemia) 
Liver abscesses 
Duodenal ulcer 
Cytomegalovirus hepatitis 
Schistosomiasis 
Choledochal cyst  
Retroperitoneal fibrosis  
Abdominal trauma  
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Portal vein malformations  
 
in children with polimalformation 
Cardiovascular diseases Budd-Chiari syndrome 
Sinusoidal obstruction syndrome 
Constrictive pericarditis 
Tricuspid insufficiency 
Tumour of the right atrium 
Table 2. Local conditions associated with high risk of PVT 
In patients with liver cirrhosis the incidence of PVT is reported to be between 6 and 17%, 
with a higher incidence in more advanced stages of the liver disease. The association 
between liver cirrhosis and hepatocellular carcinoma increases the incidence of PVT over 
44%. Additional attention should be paid in cirrhotic patients with underlying 
prothrombotic condition due to the non-specific decrease in the plasmatic level of 
coagulation inhibitors even in well-compensated liver cirrhosis. In a recent study it was 
showed that patients with chronic liver diseases, especially liver cirrhosis, have an increased 
relative risk of venous thromboembolism, contradicting the classical hypothesis of 
autoanticoagulation in cirrhotic patients (Søgaard et al., 2009). This procoagulant status was 
scientifically related to prohemostatic changes of the coagulation factors recorded in chronic 
liver diseases: elevated levels of factor VIII and von Willebrand factor concomitant with low 
levels of protein C, protein S, antithrombin-III, plasminogen and ADAMTS-13 (a naturally 
occurring plasma metalloprotease that limits in vivo functions of von Willebrand factor on 
platelets). 
Hepatocellular carcionoma and pancreatic cancer are the most frequent abdominal 
malignancies associated with PVT through a compression/invasion/hypercoagulability 
mechanisms. Hormonal factors might also play a role in this process, especially in men 
(Bick, 1992). 
Primary myeloproliferative diseases (especially polycytemia vera and essential 
thrombocythemia) are the most often cause of PVT when cirrhosis or cancer is excluded. In a 
recent study the incidence of myeloproliferative disorders are estimated to be found in 37% 
of patients with non-cirrhotic/non-malignant PVT (Kiladjian et al., 2006). These diseases are 
often asymptomatic at the moment of PVT diagnose and therefore a bone marrow biopsy is 
required. Recently the discovery of the V617F mutation of the Janus kinase 2 (JAK2) in 
patients with myeloproliferative disorders has been facilitating the diagnosis. JAK2 
mutation it has been identified in 95% of patients with polycythemia vera and in 50 to 60% 
of patients with essential thrombocythemia. Thus, JAK2 mutation it is now recommended 
by WHO as a major diagnostic criterion for myeloproliferative disorders (Tefferi et al., 2007). 
In a study on 74 women with essential thrombocythemia the incidence of thrombosis was 
18%, of which major thrombotic episodes were found in 7% (Tefferi et al., 2000). In another 
retrospective study of 102 patients with myeloproliferative disorders, the rate of 
thromboembolic complications in patients with polycythemia vera was 16.7%, 13.8% in 
patients with myelofibrosis and 7.5% in patients with essential thrombocythemia 
(Brodmann et al., 2000). The cytoreductive therapy with hydroxyurea and supplemental 
phlebotomy when necessary significantly reduced the risk of thrombosis when compared to 
control group treated with phlebotomy alone. 
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The algorithm proposed by AASLD in 2009 for the identification of the PVT etiology is 
presented in the next table. 
 
1. Check first for cirrhosis, cancer of the abdominal organs and an inflammatory focus 
in the abdomen based on initial CT scan and sonography followed by additional 
procedures, as appropriate 
2. Check for multiple, concurrent risk factors for thrombosis, in all patients without 
advanced cirrhosis or cancer 
3. Do not rule out a diagnosis of myeloproliferative disease solely on the basis of 
normal or low peripheral blood cell counts 
4. When coagulation factor levels are decreased, consider low levels of protein C, 
protein S or antithrombin as a possible consequence of liver dysfunction; consider 
inherited deficiency when screening of a first-degree relative is positive 
Table 3. Algorithm for investigating the cause of PVT (DeLeve et al., 2009) 
4. Pathophisiology 
Portal vein thrombosis is the main cause of presinusoidal portal hypertension. Frequently 
the initial placement of the thrombus is in the portal vein trunk but sometimes it is the result 
of the extension of a thrombus located on the intrahepatic branches of the portal vein or 
from the splenic vein. According to the location and extension of the thrombus, a grading 
system was proposed for a better evaluation of the disease prognosis (Naonami et al., 1992).  
 
Grade of PVT Thrombus description 
1 Occlusion of intrahepatic portal vein branches 
2 Occlusion of right or left portal vein main branches 
3 Partial occlusion of the portal vein trunk 
4 Complete occlusion of the portal vein trunk 
Table 4. PVT grading system 
As a limited form of PVT, the term of “obliterative portal venopathy” was proposed in order 
to describe the thrombosis of intrahepatic portal vein branches in the absence of liver 
cirrhosis, inflammation or hepatic neoplasia (Cazals-Hatem et al., 2011). 
Within days after the acute thrombosis of the portal vein, a cavernous transformation is 
taking place as a result of small varices proliferation around the former portal vein 
concomitant with a recanalisation of the thrombus through a neoangiogenesis process. The 
result is a spongy, tendril-like convolution of small vessels developed in the area of porta 
hepatis in order to compensate and by-pass the obstruction of the blood flow. Additionally, 
the reduced venous blood supply may be compensated by increasing arterial perfusion, 
which is documented by Doppler ultrasonography. 
Chronic portal hypertension and fibroblasts activation inside the cloth leads to the 
development of a network of tortuous small vessels inside and around the former portal 
vein acting like a by-pass for the stenotic segment of the portal vein – the so-called portal 
cavernoma. This process starts from the moment of the acute thrombosis and evolves over 
the next weeks and months together with the development of porto-portal and porto-
www.intechopen.com
Portal Vein Thrombosis with Cavernous  
Transformation in Myeloproliferative Disorders: Review Update 
 
71 
systemic collaterals until equilibrium is established between prestenotic and poststenotic 
segment of the portal vein. Moreover, the development of porto-systemic collaterals may 
lead to a deterioration of the portal encephalopathy. 
The natural history of PVT is still unclear, but two possible mechanisms can be involve in 
the asymptomatic status of the patients: one of them might be the flux augmentation in the 
hepatic artery as a compensation of the decreased flow in the portal vein; the second one 
involves the cavernous transformation with fast development of a tortuous network of 
collateral veins with periportal distribution around biliary ducts, gallbladder, gastric 
antrum, duodenu and pancreas (Henderson et al., 1992).  
PVT and development of a portal cavernoma determines a prehepatic portal hypertension 
with an elevated blood pressure in the obstructed splanhnic territory with hepatopetal 
collateral network, condition known as cavernoma (Ohnishi et al., 1984). As a consequence 
of PVT with cavernous transformation the portal biliopathy can develop (Perlemuter et al., 
1996). Another consequence might be a hyperkinetic status with higher cardiac output and 
lower vascular resistance due to portal obstruction and to portal-systemic collateral 
circulation (Ohnishi et al., 1984).  
5. Clinical features 
Clinical presentation always depends on the onset and the extent of the portal thrombosis as 
well as of the development of collateral circulation. 
5.1 Acute PVT 
In acute PVT patients can complain of abdominal pain, nausea, vomiting, fever, diarrhoea 
and haematochezia – symptoms due to intestinal congestion and ischemia. If venous 
obstruction is not quickly controlled, some severe complications might occur: enteral 
perforation, septic shock, peritonitis and exitus due to multiorgan failure. The physical 
examination reveals splenomegaly in almost all cases, whereas ascites is present before the 
onset of collateral circulation, caused by intestinal venous stasis (Kocher & Himmelmann, 
2005; Ponziani et al., 2010). 
5.2 Chronic PVT 
Usually asymptomatic, the clinical presentation for PVT is almost always 
hematemesis/melaena due to variceal bleeding. Abdominal pain is not present commonly 
unless the extension of the PVT into the mesenteric branches causes mesenteric ischemia. An 
episode of gastrointestinal bleeding is often reported as the first presenting symptom in 
about 20%-40% of cases (Hoekstra & Janssen 2009), taking into account that in patients with 
cirrhosis and PVT the risk for variceal bleeding is estimated to be more than 80-120 times 
higher than in cases without cirrohsis (Condat et al, 2001). Ascites and encephalopathy are 
rare events and only transient. They are more frequent after an episode of gastrointestinal 
bleeding or might be associated with renal failure or sepsis especially in older patients 
(Sobhonslidsuk & Reddy, 2002).  
In pylephlebitis patients usually features high fever and chills associated with painful liver 
at clinical examination.  
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Physical examination might be completely normal but, sometimes, cholestasis, cholangitis, 
choledocholithiasis, cholecystitis might occur, configuring the so-called “portal biliopathy”. 
6. Biologic and imaging studies 
Liver laboratory test are usually normal or characteristic for the underlying liver disease. A 
cholestatic syndrome can develop in PVT associated with portal biliopathy and the 
ERCP/MRCP frequently reveals a false image of cholangiocarcinoma due to the external 
compression of the common bile duct by the tortuous vessels of the cavernoma. In case of 
pylephlebitis blood culture usually reveals Bacteroides species and special attention should be 
paid for the identification of the abdominal origin of the infection. 
Beside the eso-gastric varices revealed by the upped digestive endoscopy, other collateral 
venous circulation can develop in the gallbladder, duodenal, jejunal or rectal walls.  
The abdominal ultrasound with Doppler/power-Doppler examination is the investigation 
of choice in PVT diagnose (sensitivity over 90%). It reveals the presence of the hypo- or 
hyperechoic material (depending on the age of the thrombus) inside the portal lumen. The 
examiner must bear in mind that frequently a difficult-to-identify portal vein suggests an 
old PVT. Additionally, a study from 2009 revealed that portal flow velocity below 15cm/s is 
an important predictive factor for PVT development (Søgaard et al., 2009). 
 
Fig. 1. Patient M.I. 47 years old diagnosed with ET – Doppler ultrasound revealing multiple 
small venous vessels replacing the former portal vein. 
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Fig. 2. Patient M.I. – Doppler ultrasound showing an old (hyperechoic) thrombus occluding 
the portal vein. 
The next step in the PVT diagnose algorithm is the magnetic resonance angiography with 
better results than the CT-scan in identifying the characteristic changes involving the portal 
trunk. 
 
Fig. 3. Patient M.I. - CT scan with i.v. contrast revealing hypodense thrombus and portal 
cavernoma: heterogonous mass at the level of the portal vein due to cavernouse 
transformation; homogeneous splenomegaly. 
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Contrast enhanced ultrasonography is indicated for a better visualization of the thrombus, 
in differentiating between benign and malignant thrombosis or for the disclosure of 
cavernous transformation of the portal vein. When differentiating between benign and 
malignant thrombosis the absence of contrast inside the thrombus is suggestive for benign 
cloth while contrast enhancement of the thrombus is highly suggestive for neoplastic 
invasion of the portal vein. 
Endoscopic ultrasound was recently added to the imaging armamentory showing a higher 
sensitivity and specificity than conventional ultrasound and CT/MR-scan in detecting 
small, non-occlusive thrombi and incipient malignant invasion of the portal and splenic 
veins.  
The portal venography can be useful before surgical treatment is intended. 99mTc-DTPA 
(diethylenetriamine pentaacetic acid) scintigraphy reveals only the arterial peak with the 
absence of the portal peak on the time-activity curve. 
 
Fig. 4. Patient M.I. - Coronal MRI T2 weighted FRFSE fat-sat depicting portal cavernoma: 
dilated portal vein with heterogeneous signal due to the cavernous transformation. 
Associated homogeneous splenomegaly 14 cm diameter. 
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Fig. 5. Coronal MRI T2 weighted fat-sat of the same patient. The permeable lumen having a 
thread-like hypersignal on T2 weighted image, in the center of the portal vein along with 
dilated, partially thrombotic, portal vein. 
 
Fig. 6. The same case – axial T2 weighted fat-sat. In addition to the changes of the portal vein 
the image reveals homogeneous splenomegaly; dilated, partially dilated splenic vein; portal 
type collateral venous flow. 
www.intechopen.com
 Portal Hypertension – Causes and Complications 
 
76
 
Fig. 7. The same case – axial T1 weighted fat-sat with i.v. contrast. Cavernous transformation 
of the portal vein with contrast enhancement of the fibrotic thrombi. The central thread-like 
permeable lumen shows a reduced flow signal. 
 
Fig. 8. The same case – coronal T1 weighted fat-sat with contrast. Same changes as in figure 7. 
www.intechopen.com
Portal Vein Thrombosis with Cavernous  
Transformation in Myeloproliferative Disorders: Review Update 
 
77 
 
  
Fig. 9 and 10. The same case – angio-MRI sequence. Inhomogeneous signal of the portal vein 
with chronic thrombosis. 
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7. Diagnosis algorithm 
The algorithm for PVT diagnose proposed by AASLD in 2009 is presented in the next table. 
 
Acute thrombosis Chronic thrombosis 
1. Consider a diagnosis of acute PVT 
in any patient with abdominal pain 
of more than 24 hours duration, 
whether or not there is also fever or 
ileus 
1. Consider a diagnosis of chronic 
PVT in any patient with newly 
diagnosed portal hypertension 
2. If acute PVT is suspected, CT 
scan, before and after injection of 
vascular contrast agent, should be 
obtained for early confirmation of 
diagnosis. If CT scan is not rapidly 
available, obtain Doppler- 
sonography  
2. Obtain Doppler-sonography, then 
either CT scan or MRI before and 
after a vascular contrast agent to 
make a diagnosis of chronic PVT 
3. In patients with acute PVT and 
high fever and chills, septic 
pylephlebitis should be considered, 
whether or not an abdominal source 
of infection has been identified, and 
blood cultures should be routinely 
obtained 
3. Base the diagnosis on the absence 
of a visible normal portal vein and 
its replacement with serpiginous 
veins 
4. In acute PVT, the possibility of 
intestinal infarction should be 
considered from presentation until 
resolution of pain. The presence of 
ascites, thinning of the intestinal 
wall, lack of mucosal enhancement 
of the thickened intestinal wall,or 
the development of multiorgan 
failure indicate that intestinal 
infarction is likely and surgical 
exploration should be considered 
 
Table 5. PVT diagnose algorithm (DeLeve et al., 2009) 
8. Treatment 
In patients with PVT due to septic conditions (cholangitis, diverticulitis, appendicitis, 
cholecystitis, umbilical vein infection, pylephlebitis, liver abscesses etc) the prompt initiation 
of broad-spectrum antibiotic association therapy leads to an efficient repermebilisation of 
the portal vein within days. 
If patient is diagnosed in the recent phase of the PVT (hypoechoic aspect on the ultrasound 
examination together with blood flow deviation and flux acceleration on Doppler 
examination) anticoagulant therapy is indicated in order to prevent the total obstruction of 
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the portal vein and the cavernous transformation. Standard heparin or LMWH derivates are 
initially used followed by oral dicumarinic anticoagulants in order to obtain an INR 
between 2 and 2,5 with an efficient repermeabilisation in over 80% of cases in the next six 
months (Valla et al., 2002). As for the peripheral vein thrombosis, the oral anticoagulant 
therapy is considered to be mandatory for minimum three months and usually is indicated 
for at least six months. Chronic, indefinite oral anticoagulation is recommended in patients 
with identified hypercoagulability associated diseases or in presence of thrombus extension 
into the mesenteric vein.  
However, additional concern has been rise over vitamin K antagonists indication in cirrhotic 
patients due to plasmatic low protein C levels. As protein C is a vitamin K-dependent factor 
and treatment with vitamin K antagonist may further reduce the plasmatic levels of this 
anticoagulant protein, the increasing risk for venous thrombosis has been issued. Newly 
developed direct thrombin inhibitors and inhibitors of activated factor X (e.g. dabigatran, 
rivaroxaban, apixaban) are considered to be more attractive alternatives to vitamin K 
antagonists due to their null influence over protein C levels (Franchini & Mannucci, 2009). 
In addition to their oral administration they have the advantage of not requiring regular 
laboratory monitoring (such as INR) (Tripodi & Mannucci, 2011). 
Concern has been rise also over the safety of chronic anticoagulant therapy in patients with 
esophageal varices. The few clinical studies addressing this issue (Condat et al., 2001) 
revealed no significant increase in risk and severity of variceal bleeding.  
In initially acute phases, thrombolytic medication (e.g. streptokinase, tPA, alteplase) can be 
safely initiated especially in patients associating mesenteric ischemia due to thrombus 
extension in the upper mesenteric vein (Malkowski et al., 2003).  
In patients diagnosed with old age thrombus or cavernous transformation of the portal vein 
the anticoagulant treatment is not indicated due to the lack of efficiency and the associated 
risk of bleeding.  
The major complication of PVT is upper digestive bleeding originating from the eso-gastric 
varices, with a significant lower mortality rate in patients without liver cirrhosis (aprox. 5%) 
than in patients with cirrhosis (between 30 and 70%) (Jing-Tong et al., 2005). The endoscopic 
procedures (band ligation/sclerotherapy) are the first-line treatment indicated in these cases 
with multiple sessions until the occlusion of the varices. A special attention should be paid 
when indicating vasoconstrictive agents (e.g. glipresin, terlipresin) due to the possibility of 
inducind extended intestinal ischemia. Associated oral medication (nonselective beta-
blockers +/- long-acting nitrates) prevents the recurrent bleeding. In refractory cases of 
variceal bleeding and in gastric valices TIPS placement is considered. Malignant portal vein 
invasion/thrombosis can be safely managed with percutaneous stenting.  
More invasive surgical treatment (mesocaval/splenorenal shunts, eso-gastric 
devascularization) may be necessary in patients with uncontrolled bleeding.  
In children it has been recommended the mesenteric-to-left portal vein bypass with very 
good results in term of rebleeding prevention and improvement of cognitive function. 
Initially considered as contraindication for liver transplantation, the complete PVT is now 
considered to be just a relative contraindication but only in case the superior mesenteric vein 
is permeable. Partial PVT can be managed by thrombectomy or by-pass techniques. 
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Portal biliopathy is another potential complication developing in the evolution of PVT with 
cavernous transformation. It consists in multiple, successive stenosis involving the common 
bile duct and the hepatic duct as a result of extrinsic compression and/or ischemic fibrosis 
of the biliary tract. In symptomatic patients (cholangitis, cholecystitis, biliary stones in the 
CBD, secondary biliary cirrhosis) the portal biliopathy can be addressed with 
sphincterothomy, stone extraction, stricture dilatation and biliary stanting together with a 
porto-systemic shunt in order to reduce the external compression of the biliary tract.  
From the systemic conditions associated with portal cavernoma, the myeloproliferative 
syndrome is by far the most frequent one (37% of patients with non-cirrhotic non-malignant 
PVT) (Kiladjian et al., 2006). To prevent thrombotic complication in chronic 
myeloproliferative disorders, platelet-lowering agents are used to address the 
thrombocitemia-associated risk. Hydroxyurea, a ribonucleotide reductase inhibitor with 
myelosuppressive action, is the first line indication administered on a 500mg PO bid 
regimen. A platelet-specific lowering agent (Anagrelide) is available on a 0,5mg PO tid 
regimen for the patients with intoleration to hydroxyurea. For a more efficient 
myelosuppressive action Interferon-alpha is recommended on a 5MU SC tiw regimen. 
Despite their leukemogenic action, radiophosphorus (32P) and alkylating agents (e.g. 
chlorambucil) may be useful as backup regimens in case of recurrent disease (Tefferi et al., 
2001). The goal of platelet-lowering medication is to maintain the platelet level under 
400000/mm3 in the high-risk patients (Regev et al., 1997; Storen & Tefferi, 2001).  A more 
aggressive approach like bone marrow transplantation should be considered only in 
exceptional cases. 
9. Prognosis 
In the absence of liver cirrhosis and neoplasia the development of portal cavernoma is 
usually asymptomatic until the first variceal bleeding and has a better prognosis in 
comparison with variceal bleeding caused by cirrhosis (Janssen et al., 2001).  
Except the variceal bleeding, the natural history of portal cavernoma is unremarkable until 
the development of two other complications: intestinal ischemia (due to extension of the 
thrombus in the mesenteric vein) and portal biliopathy (common bile duct dilation with 
cholestatic syndrome). 
Although ET usually carries the best prognosis among the MPD, portal vein thrombosis was 
identified as a risk factor for poor survival, which appears to be the result of increased 
mortality from acute leukemic or myelofibrotic transformation and hepatic failure (Gangat 
et al., 2006). 
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